Synagis (palivizumab) 50 mg/0.5 mL solution for injection, 1 vial (AbbVie) Prevention of severe lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at high risk of RSV infection, +380996042415

Prophylaxis of severe lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at high risk of RSV infection, including: children under 6 months of age born at or before 35 weeks of gestation; children under 2 years of age who have required treatment for bronchopulmonary dysplasia within the past 6 months; children under 2 years of age with hemodynamically significant congenital heart defects.